GlaxoSmithKline, the London-based pharmaceutical giant with a substantial presence in Montgomery County and Philadelphia, announced a landmark investment ...

GSK's new HIV and cancer treatments lifted profit ahead of analysts' expectations in the third quarter despite lower vaccines sales on weak demand in the U.S.

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

Following outlays for sites in the UK and Belgium earlier this year, GSK is planning to invest up to $800m in the US to double the size and capacity of its site in Marietta, Pennsylvania.

Image credit: Shutterstock/ Golden Shrimp. Following outlays for sites in the UK and Belgium earlier this year, GSK is planning to invest up to $800m in the US to double the size and capacity of its ...

GSK (LSE: GSK) has announced its largest US manufacturing investment ... manufacturing and additional drug product manufacturing capabilities to the company’s site in Marietta, Pennsylvania, along ...

Additionally, GSK will establish a new vaccines drug substance facility at the site, dedicated to manufacturing products based on the company’s novel MAPS technology, subsequent to future ...

Those investments included a 67 million pound upgrade to GSK's manufacturing site in Montrose, Scotland, to beef up production of active pharmaceutical ingredients.

MONTROSE, Colo. (KREX) – A federal grand jury indicted a Montrose man and former FBI agent for a foreign currency – or forex – trading scheme, U.S. Attorney Dawn Ison said. Jeffrey Royer, 61 ...

planning application with Dublin City Council for its €107.5 million former RTÉ site next year. An Bord Pleanala granted a ten year planning permission to Cairn Homes Montrose Ltd in July, ...

A Montrose resident and former FBI agent was arrested Thursday on fraud allegations in a foreign currency trading scheme. The FBI, assisted by the Montrose police, arrested Jeffrey A. Royer ...

The update on the GSK-partnered prospect sent Wave’s share price up 63% to almost $14 despite coinciding with news that Takeda has axed a deal for another asset. The ongoing phase 1b/2a study is ...